American Oncology Network to Participate in 11 Sessions at 2026 Community Oncology Alliance Annual Conference

American Oncology Network (NYSE:AONC) will speak at the 2026 Community Oncology Alliance Annual Conference, April 28-29 in Orlando.

Rhea-AI Summary

American Oncology Network (NYSE:AONC) will speak at the 2026 Community Oncology Alliance Annual Conference, April 28-29 in Orlando. AON leaders will deliver 11 sessions on topics including CAR T, radiopharmaceuticals, clinical trials, payer data, patient advocacy and careers in community oncology. AON will exhibit at booth 207.

Argus Apr 22 session

+16.13% close to close Open Argus

Details

News Market Reaction – AONC

On Apr 22, the day this news came out, AONC closed 16.13% above the previous close.

Data tracked by StockTitan Argus for the Apr 22 session.

Market Context

On Apr 22, the day this news came out, the stock closed 16.1% above the previous close. A strong pos...

Analysis

On Apr 22, the day this news came out, the stock closed 16.1% above the previous close. A strong positive reaction aligns with AON’s ongoing narrative of expansion and innovation in community oncology. Recent news highlighted new partner practices, physician additions, and data alliances aimed at broader access to advanced therapies and trials. Investors reviewing such a move could weigh how much of this growth story was already reflected in the prior trend below the 200-day MA at $9.23 and whether enthusiasm might outpace execution risk.

Key Figures

Conference sessions: 11 sessions Conference dates: April 28-29 Exhibit booth: Booth 207 +5 more

Conference sessions

11 sessions

AON participation at 2026 COA Annual Conference

Conference dates

April 28-29

2026 Community Oncology Alliance Annual Conference in Orlando, Florida

Exhibit booth

Booth 207

AON exhibit location at the 2026 COA conference

Practice locations

18 locations

Oncology Consultants locations across South Texas (Mar 5, 2026 news)

Medical oncologists

16 medical oncologists

Oncology Consultants staffing across South Texas (Mar 5, 2026 news)

Radiation oncologists

3 radiation oncologists

Oncology Consultants staffing across South Texas (Mar 5, 2026 news)

Advanced practitioners

23 advanced practitioners

Oncology Consultants staffing across South Texas (Mar 5, 2026 news)

Indiana locations

6 locations

Hematology Oncology of Indiana practice footprint (Feb 3, 2026 news)

Historical Context

5 past events · Latest: Mar 05

5 events

1. Mar 05

   Practice partnership

   24h Move

   -7.3%

   Oncology Consultants joined AON, expanding locations and clinical resources in Texas.

2. Feb 04

   New state partner

   24h Move

   +4.3%

   RKV Medical Center became AON’s first Oklahoma partner practice to broaden access.

3. Feb 03

   Physician addition

   24h Move

   +4.3%

   Hematology Oncology of Indiana welcomed Dr. Amy Braden to expand oncology services.

4. Jan 21

   Staff expansion

   24h Move

   -36.6%

   Genesis Cancer and Blood Institute added endocrinology services via new hires in Arkansas.

5. Jan 15

   Data alliance

   24h Move

   -36.6%

   Alliance with MiBA to embed AI-powered real-world data into clinical research.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

car t, radiopharmaceuticals, clinical trials, bispecific therapies, +1 more

5 terms

car t medical

"topics, including innovative therapies such as CAR T, the importance of high-quality data"

CAR T is a type of immunotherapy that reprograms a patient’s own white blood cells to recognize and attack cancer cells, like giving immune cells a custom GPS to find and destroy tumors. It matters to investors because CAR T therapies can offer durable responses for hard-to-treat cancers, but they also involve complex manufacturing, high costs, regulatory hurdles and market access challenges that affect a company’s revenue potential and risk profile.

radiopharmaceuticals medical

"patient advocacy, clinical trials, radiopharmaceuticals, and careers in community oncology."

Radiopharmaceuticals are medicines that carry tiny amounts of radioactive material to help doctors see or treat disease inside the body, acting like a tracer dye for imaging or a microscopic guided missile for targeted therapy. They matter to investors because their safety, regulatory approval, production complexity, short shelf life and hospital reimbursement determine how quickly they can reach patients and generate revenue, affecting a company’s sales potential and risk profile.

clinical trials medical

"patient advocacy, clinical trials, radiopharmaceuticals, and careers in community oncology."

Clinical trials are carefully controlled studies that test whether a new drug, device or treatment is safe and effective in people, moving through successive stages that increase the number of participants and the rigor of testing. Investors care because trial outcomes determine whether a product can be approved and sold, shaping a company’s future revenue, valuation and risk profile—think of it as proof-of-concept testing that decides if a prototype becomes a market-ready product.

bispecific therapies medical

"one of the first outpatient community-based T-cell-engaging programs, featuring both outpatient bispecific therapies"

Bispecific therapies are engineered drugs that can bind two different biological targets at the same time — like a two-headed key that fits two locks simultaneously. By linking a disease cell to the immune system or blocking two disease pathways at once, they can be more effective than single-target treatments. Investors care because bispecifics can offer stronger clinical benefits and new market opportunities, but they also involve higher development and regulatory risk.

car-t cell therapy medical

"featuring both outpatient bispecific therapies and CAR-T cell therapy, and how this approach"

A therapy that takes a patient’s own immune cells, reprograms them in a lab to recognize and attack specific disease cells, then returns them to the body—think of training and equipping a guard dog to find a particular intruder. Investors care because these treatments can offer dramatic clinical benefits, carry high development and manufacturing costs, and create new, often lucrative markets if they receive regulatory approval and payer support.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

AON leaders to speak on panels focused on advocacy, innovation and access in independent community oncology

FORT MYERS, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- American Oncology Network (AON), one of the nation’s fastest-growing community oncology networks, today announced it will participate in 11 speaking sessions at the 2026 Community Oncology Alliance (COA) Annual Conference. The event, themed Innovation in Practice, will take place April 28-29 in Orlando, Florida.

“At AON, we are committed to advancing community oncology through innovation that supports local practices and improves patient outcomes,” said Stephen “Fred” Divers, MD, AON’s chief medical officer, medical oncologist at Genesis Cancer and Blood Institute, and officer-at-large on COA’s Executive Committee. “The conference provides an important platform to share forward-thinking strategies, from new care delivery models to emerging therapies, that are transforming how care is delivered in community settings. I look forward to hearing AON thought leaders share insights with fellow community oncology colleagues.”

AON leaders will speak on a range of topics, including innovative therapies such as CAR T, the importance of high-quality data for smarter payer contracting, patient advocacy, clinical trials, radiopharmaceuticals, and careers in community oncology. Featured speakers include:

• Stephen “Fred” Divers, MD, AON chief medical officer, oncologist and hematologist at AON partner practice, Genesis Cancer and Blood Institute, and officer-at-large on COA’s Executive Committee – The Quality of Community Oncology: Presenting the COA Quality & Value Study
• Alti Rahman, MHA/MBA, CSSBB, AON chief strategy and innovation officer and COA board member – Better Data, Better Decisions: Leveraging Transparency for Smarter Contracting
• Ralph Boccia, MD, FACP, AON medical director of research and oncologist and hematologist at AON partner practice, The Center for Cancer and Blood Disorders – CAR T Comes to Main Street: Expanding Access, Empowering Care. Dr. Boccia will discuss how AON has developed one of the first outpatient community-based T-cell-engaging programs, featuring both outpatient bispecific therapies and CAR-T cell therapy, and how this approach is expanding access to advanced treatments within community clinics.
• Katie Alexander, MS, APRN-CNP, AOCNP, BBA, nurse practitioner at AON partner practice, The Zangmeister Cancer Center, and AON central region APP coordinator – The Value of Innovative Therapies for Patients
• Tyler Fugere, MD, oncologist and hematologist at AON partner practice, Genesis Cancer and Blood Institute – What I Wish I’d Known: First-Year Insights After Fellowship
• James Gilmore, PharmD, AON chief pharmacy and clinical services officer – Access & Affordability in the Era of Innovation: Cellular Therapies in Community Oncology
• Jim Chen, MD, oncologist and hematologist at AON partner practice, Genesis Cancer and Blood Institute – Community Oncology as a Career: Voices from the Frontlines
• Sunshine Maracle, AON national event and partnership manager and physician liaison at AON partner practice, Hope Cancer Care of Nevada – CPAN Advocates in Action
• Guy Messer, AS-NMT, BS-HCM, MBA, AON vice president of radiation and radiology services – Building an Innovative and Financially Sustainable Radiopharmaceutical Program
• Emily Whitman, MD, oncologist and hematologist at AON partner practice, Zangmeister Cancer Center – Multidisciplinary Physician Collaboration Driving Innovation in Community Oncology
• Julio Peguero, MD, medical director of research and oncologist at AON partner practice, Oncology Consultants – Expanding Clinical Trial Access in Community Oncology: Tech Tools and Support Strategies
  

“AON and COA share a mission to protect and promote independent oncology, while embracing the innovation required to meet the evolving needs of patients,” said Alti Rahman, AON chief strategy and innovation officer and COA board member. “By bringing together leaders from across the country, this conference fosters collaboration and accelerates the adoption of data-driven insights, advanced technologies and new care models that are redefining what is possible in community oncology.”

AON provides comprehensive support services to independent oncology practices, including in-house pharmacy, lab services, revenue-diversifying programs and back-office operations. By partnering with AON, physicians can focus on delivering high-quality, patient-centered care in their communities without relying on hospital systems or third-party providers.

AON will also exhibit at booth 207 during the conference.

For more information about AON, visit AONcology.com.

About American Oncology Network
American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 350 providers practicing across 21 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. For more information, please visit AONcology.com or follow us on LinkedIn, Facebook, X (formerly Twitter) and YouTube.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d832e063-a9fd-48c4-9498-95ee8d61bfde

Media Contact:
Karen Riley Sawyer
American Oncology Network
Karen.Sawyer@AONcology.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will American Oncology Network (AONC) present at the 2026 COA Annual Conference?

AON will participate April 28-29, 2026 with leaders in 11 speaking sessions. According to the company, AON will cover CAR T, radiopharmaceuticals, clinical trials, payer data and patient advocacy and will also exhibit at booth 207 during the Orlando event.

What topics will AONC cover in its 11 sessions at the COA 2026 conference?

AON will address CAR T, radiopharmaceuticals, clinical trials, payer contracting, advocacy and careers. According to the company, sessions include outpatient T-cell programs, data-driven contracting, multidisciplinary collaboration and strategies to expand trial access in community clinics.

Which AONC executives and clinicians are speaking at the COA 2026 conference?

Speakers include AON chief medical officer Stephen Divers and chief strategy officer Alti Rahman, among others. According to the company, presenters span clinical, pharmacy, research and operations roles from AON partner practices and central leadership.

How does AONC describe its role in expanding access to advanced therapies at COA 2026?

AON says it has developed outpatient community-based T-cell and bispecific programs to expand access to advanced therapies. According to the company, these programs aim to bring CAR T and cellular approaches into community clinics outside major hospital systems.

Will AONC offer materials or an exhibit at the COA 2026 conference?

Yes — AON will exhibit at booth 207 during the April 28-29 conference. According to the company, the exhibit will showcase AON support services such as in-house pharmacy, lab services, revenue-diversifying programs and back-office operations for community oncology practices.